Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Percutaneous Coronary (PC) Procedures

NCT00209547 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00209547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00209547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Percutaneous Coronary (PC) Procedures
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2004
Completion date
March 31, 2005
Enrollment
110
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

angioplasty, coronary catheterization